Isolated tyrosinase derived peptides and uses thereof
| Title: | Isolated tyrosinase derived peptides and uses thereof |
|---|---|
| Patent Number: | 5,843,688 |
| Publication Date: | December 01, 1998 |
| Appl. No: | 08/583,238 |
| Application Filed: | January 05, 1996 |
| Abstract: | The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention. |
| Inventors: | Wolfel, Thomas (Mainz, DEX); Van Pel, Aline (Brussels, BEX); Brichard, Vincent (Brussels, BEX); Boon-Falleur, Thierry (Brussels, BEX); DePlaen, Etienne (Brussels, BEX); Coulie, Pierre (Brussels, BEX); Renauld, Jean-Christophe (Brussels, BEX); Lethe, Bernard (Brussels, BEX) |
| Assignees: | Ludwig Institute For Cancer Research (New York, NY) |
| Claim: | We claim |
| Claim: | 1. A method for identifying a subject for treatment with a therapeutic agent which is specific for complexes of an HLA molecule and a tyrosinase derived peptide consisting of the amino acid sequence of SEQ ID NO: 4, wherein said complexes are present on surfaces of abnormal cells of said subject, comprising |
| Claim: | (i) contacting a sample containing abnormal cells, which has been taken from said subject, with a cytolytic T cell specific of said complexes |
| Claim: | (ii) determining lysis of at least some of said abnormal cells as an indication that the subject is a candidate for said treatment. |
| Claim: | 2. Isolated cytolytic T cell specific for a complex of HLA-A2 and the tyrosinase derived peptide consisting of the amino acid sequence of SEQ ID NO: 4. |
| Claim: | 3. A method for identifying abnormal cells which present complexes of an HLA molecule and a tyrosinase derived peptide consisting of the amino acid of SEQ ID NO: 4 on their surfaces, comprising contacting a sample which contains said abnormal cells with a cytolytic T cell specific for said complexes and determining lysis of said abnormal cells by said cytolytic T cells as a determination of said abnormal cells. |
| Current U.S. Class: | 435/724; 4241/931; 530/328 |
| Current International Class: | G01N 3353; A61K 39385; A61K 3804 |
| Patent References Cited: | 4898814 February 1990 Kwon |
| Other References: | Traversari et al., Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T Lymphocytes, Immunogenetics 35: 145-152, Abstract, first sentence, p. 146, column 2, "CTL clones", p. 147, column 1. 1992. Greenberg, Therapy of murine leukemia with cyclophosphamide and immune lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia, J. Immunology, vol. 136, No. 5, p. 1917, column 2, 1st sentence of the 1st paragraph. Mar. 1986. Ruppert et al., Multiple transcripts of the mouse tyrosinase gene are generated by alternative splicing, The EMBO J. vol. 7, No. 9, pp. 2715-2722, p. 2715, column 1, lines 5-7. Jun. 1988. Brichard, et al, "The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas", J. Exp. Med. 178: 489-495 (1993). Coulie, et al, "Genes Coding For Tumor Antigens Recognized by Human Cytolytic T Lymphocytes", J. Immunotherapy 14: 104-109 (1993). Slingluff, et al, "Recognition of Human Melanoma Cells by HLA-A2.1 Restricted Cytotoxic T Lymphocytes As Mediated By At Least Six Shared Peptide Epitopes", J. Immunol. 150(7): 2955-2963 (Apr. 1, 1993). Barinaga, "Getting Some `Backbone`: How MHC Binds Peptides" Science 257: 880-881 (Aug. 14, 1992). Wolfel, et al, "Lysis of Human Melanoma Cells by Autologous Cytolytic T Cells Clones", J. Exp. Med. 170: 797-810 (Sep. 1989). |
| Primary Examiner: | Achutamurthy, Ponnathapura |
| Assistant Examiner: | Park, Hankyel T. |
| Attorney, Agent or Firm: | Felfe & Lynch |
| Accession Number: | edspgr.05843688 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|